Congenital Heart Disease Global Clinical Trials Review, H1, Market Trends, Regulations And Competitive Landscape 2016

The Report Congenital Heart Disease Global Clinical Trials Review, H1, 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

GlobalData’s clinical trial report, Congenital Heart Disease Global Clinical Trials Review, H1, 2016″ provides an overview of Congenital Heart Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Congenital Heart Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Download Sample copy of this Report at:


– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Reasons to buy

– Assists in formulating key business strategies with regards to investment

– Helps in identifying prominent locations for conducting clinical trials which saves time and cost

– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

– Supports understanding of trials count and enrollment trends by country in global therapeutics market

– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

– Facilitates clinical trial assessment of the indication on a global, regional and country level

Browse Latest News at

Table Of Content

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Congenital Heart Disease to Cardiovascular Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Congenital Heart Disease to Cardiovascular Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Congenital Heart Disease Therapeutics Clinical Trials 28

Prominent Drugs 30

Latest Clinical Trials News on Congenital Heart Disease 31

Mar 23, 2016: Mezzion Pharma Receives Special Protocol Assessment Agreement From FDA For Udenafil Phase 3 Studies In Adolescents With Single Ventricle Congenital Heart Disease With Fontan Physiology 31

Clinical Trial Profile Snapshots 32

Appendix 181

Abbreviations 181

Definitions 181

Research Methodology 182

Secondary Research 182

About GlobalData 183

Contact Us 183

Disclaimer 183

Source 184

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074